Fio de Eletrodo de Taça de Ouro EEG Reutilizável

Informação básica

• Disponível em:
• English
• Português

Introducing the EarlyTect Colon Cancer Test, a groundbreaking product in the field of colorectal cancer screening. This test has been rigorously tested and approved by the Korea Ministry of Food and Drug Safety, with clinical trials conducted at renowned institutions such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center.

Designed specifically for eligible subjects aged 30 to 80, the EarlyTect Colon Cancer Test utilizes advanced technology to detect colorectal cancer with exceptional accuracy. Using a qualitative real-time PCR test, it measures the levels of methylated Syndecan-2, a biomarker strongly associated with precancerous lesions of colorectal cancer, in stool DNA.

Clinical trials have demonstrated that this test achieves an impressive 90% sensitivity and specificity in diagnosing colorectal cancer. However, it is important to note that the EarlyTect Colon Cancer Test is not intended to conclusively confirm the presence of colorectal cancer. Rather, a positive result indicates the potential existence of colorectal cancer or precancerous lesions of colorectal cancer, warranting further medical investigations.

The EarlyTect Colon Cancer Test adheres to stringent product standards. It is specifically designed for colorectal cancer screening, targeting asymptomatic individuals. The biomarker used in the test is SDC2 methylation, a reliable indicator of colorectal cancer risk.

For pricing and transaction details, we offer flexible negotiations to meet your specific requirements. Please kindly request a quote to proceed with the transaction.

With the EarlyTect Colon Cancer Test, early detection and timely intervention become crucial allies in the fight against colorectal cancer.